CureTech 
Welcome,         Profile    Billing    Logout  
 1 Product   110 Diseases  1 Product   1 Trial   94 News 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
pidilizumab (CT-011) / CureTech
NCT01067287: Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation

Active, not recruiting
2
35
US, RoW
CT-011, Dendritic Cell Fusion Vaccine
Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Rambam Health Care Campus, Gateway for Cancer Research, United States Department of Defense
Multiple Myeloma
09/25
12/25
NCT06560827: CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection

Recruiting
1
30
RoW
CT011 CAR-GPC3 T Cells Injection
CARsgen Therapeutics Co., Ltd., Shanghai Zhongshan Hospital
HCC
12/26
06/27
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
pidilizumab (CT-011) / CureTech
NCT01067287: Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation

Active, not recruiting
2
35
US, RoW
CT-011, Dendritic Cell Fusion Vaccine
Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Rambam Health Care Campus, Gateway for Cancer Research, United States Department of Defense
Multiple Myeloma
09/25
12/25
NCT06560827: CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection

Recruiting
1
30
RoW
CT011 CAR-GPC3 T Cells Injection
CARsgen Therapeutics Co., Ltd., Shanghai Zhongshan Hospital
HCC
12/26
06/27

Download Options